<?xml version="1.0" encoding="UTF-8"?>
<p id="p0090">Remdesivir (GS-5734) is an antivirus unapproved drug candidate that was developed by Gilead Sciences (Foster City, CA, USA) to combat the West African Ebola virus disease epidemic in the mid-2010s. This nucleotide prodrug has also shown activity against the hemorrhagic fever Marburg virus (MARV), the SARS-coV and MERS-coV). However, it is administrated only intravenously [
 <xref rid="bib49" ref-type="bibr">[49]</xref>, 
 <xref rid="bib50" ref-type="bibr">[50]</xref>, 
 <xref rid="bib51" ref-type="bibr">[51]</xref>]. Anti-HIV drug lopinavir is developed from ritonavir. Both are created against HIV-1 protease. Lopinavir/ritonavir combination as a single medication is known as Kaletra®, effective drug, approved by FDA in 2001 for the treatment of HIV infection in adults [
 <xref rid="bib52" ref-type="bibr">52</xref>,
 <xref rid="bib53" ref-type="bibr">53</xref>]. Favipiravir (T-705, Avigan®) is a pyrazinecarboxamide molecule, capable of converting into the cell into a nucleoside analog, ribonucleotide T-705-4-ribofuranosyl-5′-monophosphate, which inhibits the activity of viral RNA polymerase without affecting cellular synthesis of RNA or DNA. This antiviral drug was developed in Japan and approved in 2014 for treating viral strains unresponsive to current antivirals [
 <xref rid="bib54" ref-type="bibr">54</xref>,
 <xref rid="bib55" ref-type="bibr">55</xref>]. Chloroquine (Resochin®, Aralen®) and hydroxychloroquine (Dolquine®, Plaquenil®, Axemal®) are antimalarial drugs. The latter drug is also used in rheumatoid arthritis and lupus treatments. Both drugs possess a high level of toxicity, especially, cardiotoxicity [
 <xref rid="bib56" ref-type="bibr">[56]</xref>, 
 <xref rid="bib57" ref-type="bibr">[57]</xref>, 
 <xref rid="bib58" ref-type="bibr">[58]</xref>, 
 <xref rid="bib59" ref-type="bibr">[59]</xref>].
</p>
